Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography
Creators
- 1. Department of Nuclear Medicine, 'Alexandra' University Hospital, Athens (Greece)
- 2. Department of Internal Medicine, 'Metropolitan' Hospital, Athens (Greece)
- 3. Department of Radiology, 'Alexandra' University Hospital, Athens (Greece)
- 4. Institute of Radioisotopes - Radiodiagnostic Products, National Center for Scientific Research 'Demokritos', Athens (Greece)
- 5. Department of Pathology, 'Alexandra' University Hospital, Athens (Greece)
- 6. Department of Pathology, University of Athens School of Medicine, Athens (Greece)
- 7. Department of Obstetrics and Gynecology, 'Alexandra' University Hospital, Athens (Greece)
Description
The aim of the study was to retrospectively define specific features of the technetium-99m pentavalent dimercaptosuccinic acid (99mTc-(V)DMSA) and technetium-99m 2-methoxy isobutyl isonitrile (99mTc-Sestamibi [99mTc-MIBI]) distribution in ductal breast carcinoma in situ and lobular breast carcinoma in situ (DCIS/LCIS), in relation to mammographic, histological and immunohistochemical parameters. One hundred and two patients with suspicious palpation or mammographic findings were submitted preoperatively to scintimammography (a total of 72 patients with 99mTc-(V)DMSA and a total of 75 patients with 99mTc-Sestamibi, 45 patients receiving both radiotracers). Images were acquired at 10 min and 60 min, and were evaluated for a pattern of diffuse radiotracer accumulation. The tumor-to-background ratios were correlated (T-pair test) with mammographic, histological and immunohistochemical characteristics. Histology confirmed malignancy in 46/102 patients: 20/46 patients had DCIS/LCIS, with or without coexistent invasive lesions, and 26/46 patients had isolated invasive carcinomas. Diffuse 99mTc-(V)DMSA accumulation was noticed in 18/19 cases and 99mTc-Sestamibi in 6/13 DCIS/LCIS cases. Epithelial hyperplasia demonstrated a similar accumulation pattern. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value for each tracer were calculated. Solely for 99mTc-(V)DMSA, the tumor-to-background ratio was significantly higher at 60 min than at 10 min and the diffuse uptake was significantly associated with suspicious microcalcifications, with the cell proliferation index ≥ 40% and with c-erbB-2 ≥ 10%. 99mTc-(V)DMSA showed high sensitivity and 99mTc-Sestamibi showed high specificity in detecting in situ breast carcinoma (99mTc-(V)DMSA especially in cases with increased cell proliferation), and these radiotracers could provide clinicians with preoperative information not always obtainable by mammography
Availability note (English)
Available from http://dx.doi.org/10.1186/bcr948; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064097Additional details
Identifiers
Publishing Information
- Journal Title
- Breast Cancer Research (Print)
- Journal Volume
- 7
- Journal Issue
- 1
- Journal Page Range
- p. 33-45
- ISSN
- 1465-5411
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47028903
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BIOMEDICAL RADIOGRAPHY; BUILDUP; CARCINOMAS; CELL PROLIFERATION; COST; ECONOMICS; INDEXES; MAMMARY GLANDS; PATIENTS; SENSITIVITY; SOCIO-ECONOMIC FACTORS; SPECIFICITY; TECHNETIUM 99; TRACER TECHNIQUES
- Descriptors DEC
- BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BODY; DIAGNOSTIC TECHNIQUES; DISEASES; DOCUMENT TYPES; GLANDS; HOURS LIVING RADIOISOTOPES; INSTITUTIONAL FACTORS; INTERMEDIATE MASS NUCLEI; INTERNAL CONVERSION RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPE APPLICATIONS; ISOTOPES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ORGANS; RADIOISOTOPES; RADIOLOGY; TECHNETIUM ISOTOPES; YEARS LIVING RADIOISOTOPES
Optional Information
- Copyright
- Copyright (c) 2004 Papantoniou et al., licensee BioMed Central Ltd.
- Notes
- PMCID: PMC1064097; PUBLISHER-ID: bcr948; PMID: 15642168; OAI: oai:pubmedcentral.nih.gov:1064097